Press Releases

WASHINGTON, DC, September 22, 2017 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cellular therapies and broader regenerative medicine sector, today sent a letter to U.S. Sens. Graham (R-SC), Cassidy, MD (R-LA), Heller (R-NV) and Johnson (R-WI), detailing concerns regarding the American Health Care Act (H.R. 1628).

WASHINGTON, DC, September 6, 2017 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, today released the agenda for its upcoming three-day Cell & Gene Meeting on the Mesa annual conference, October 4-6, 2017.

WASHINGTON, D.C., August 30, 2017 - The Alliance for Regenerative Medicine has issued the following statement: 
The FDA’s approval of Novartis’s CAR T-cell therapy Kymriah is a historic and monumental milestone for patients and the broader regenerative medicine sector. Great potential has become thrilling reality with the approval of what will likely be a cure for patients with B-cell acute lymphoblastic leukemia (ALL).

WASHINGTON, D.C., August 18, 2017 – The Alliance for Regenerative Medicine (ARM) released today its most recent quarterly data report, offering an in-depth look at cell therapy, gene therapy, tissue engineering and broader global regenerative medicine sector trends and metrics in the second quarter and first half of 2017.

WASHINGTON, DC, July 27, 2017 – The Alliance for Regenerative Medicine (ARM) has issued the following statement in response to the news that a research team from the Oregon Health and Science University has, for the first time in the United States, utilized gene editing technology to modify human embryos:

WASHINGTON, D.C., July 24, 2017 – The Alliance for Regenerative Medicine (ARM) today announced the publication of its reimbursement and market-access focused white paper, “New Payment and Financing Models for Curative Regenerative Medicines,” available online today in In Vivo.

WASHINGTON, DC, July 19, 2017 – The Alliance for Regenerative Medicine (ARM) today announced the initial slate of companies selected to present at its upcoming Cell & Gene Meeting on the Mesa annual conference, October 4-6, 2017.

Over the course of the three-day conference, more than 850 are expected to attend, including executives from leading companies, venture capital and institutional investors, tools and development platform providers, clinicians, patients and patient advocates, life-science media and more.

WASHINGTON, DC, July 12, 2017 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cellular therapies and broader regenerative medicine sector, has issued the following statement in response to today’s U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee meeting discussing Novartis’ biologics license application for tisagenlecleucel, the company’s anti-CD19 CAR-T product for the treatment of pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL):

WASHINGTON, DC, June 27, 2017 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cellular therapies and broader regenerative medicine sector, formally announces that its Board of Directors has named Janet Lynch Lambert as the organization’s first chief executive officer. The organization informed its membership early last week of the decision.

WASHINGTON, DC, May 11, 2017 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cellular therapies and broader regenerative medicine sector, announced the speaker line up for its eighth Annual Dinner and Legislative Fly-In, to be held May 23 and 24 in Washington, D.C. This event honors recent accomplishments in the sector and enables ARM members to advocate on Capitol Hill for legislative support of gene and cellular therapies and other regenerative medicines.

Pages